Phosphodiesterase 10A inhibitors: analysis of US/EP patents granted since 2012-Reference-Cited by-同舟云学术

Phosphodiesterase 10A inhibitors: analysis of US/EP patents granted since 2012

Published:2015-05 Issue:3 Volume:4 Page:161-186
ISSN:2046-8954
Container-title:Pharmaceutical Patent Analyst
language:en
Short-container-title:Pharmaceutical Patent Analyst

Author:

Bartolomé-Nebreda José-Manuel¹,Conde-Ceide Susana¹,García María²

Affiliation:

1. Neuroscience Medicinal Chemistry, Janssen Research & Development, Jarama 75, Toledo 45007, Spain

2. Johnson & Johnson Patent Law Department, Turnhoutseweg 30, B-2340, Beerse, Belgium

Abstract

Phosphodiesterases are enzymes that metabolically inactivate the intracellular second messengers 3′,5′-cyclic adenosine and guanosine monophosphate contributing to the control of multiple biological processes. Among them, PDE10A has the most restricted distribution with high expression in striatal medium spiny neurons. Dysfunction of this key brain circuit has been associated with different psychiatric and neurodegenerative disorders. The unique role of PDE10A, together with its increased pharmacological characterization, have prompted enormous interest in investigating the potential of inhibitors of this enzyme as potential novel therapeutic agents This article reviews PDE10A related patents issued in the period 2012–2014 in the USA and Europe offering also a perspective on potential avenues for the future clinical development of phosphodiesterase 10A inhibitors.

Publisher

Future Science Ltd

Subject

General Medicine

Link

http://www.future-science.com/doi/pdf/10.4155/ppa.15.11

Reference143 articles.

1. Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling

2. Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions

3. Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments

4. Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents

5. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington’s Disease;Journal of Medicinal Chemistry;2022-12-09

2. Whole genome analysis and specific PCR primer development for Vibrio coralliilyticus, combined with transcription and metabolome analysis of red spotting disease in the sea urchin, Strongylocentrotus intermedius;Aquaculture Reports;2022-02

3. Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors;ACS Chemical Neuroscience;2020-02-27

4. Discovery of a pyrazolo[1,5-a]pyrimidine derivative (MT-3014) as a highly selective PDE10A inhibitor via core structure transformation from the stilbene moiety;Bioorganic & Medicinal Chemistry;2019-08

5. Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors;Journal of Medicinal Chemistry;2019-03-19